1. Home
  2. ACOG vs QNCX Comparison

ACOG vs QNCX Comparison

Compare ACOG & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACOG
  • QNCX
  • Stock Information
  • Founded
  • ACOG 2000
  • QNCX 2012
  • Country
  • ACOG Canada
  • QNCX United States
  • Employees
  • ACOG N/A
  • QNCX N/A
  • Industry
  • ACOG
  • QNCX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ACOG
  • QNCX Health Care
  • Exchange
  • ACOG Nasdaq
  • QNCX Nasdaq
  • Market Cap
  • ACOG 80.3M
  • QNCX 47.7M
  • IPO Year
  • ACOG N/A
  • QNCX 2019
  • Fundamental
  • Price
  • ACOG $10.69
  • QNCX $1.64
  • Analyst Decision
  • ACOG Strong Buy
  • QNCX Strong Buy
  • Analyst Count
  • ACOG 1
  • QNCX 5
  • Target Price
  • ACOG $20.00
  • QNCX $8.00
  • AVG Volume (30 Days)
  • ACOG 71.5K
  • QNCX 353.3K
  • Earning Date
  • ACOG 08-14-2025
  • QNCX 08-12-2025
  • Dividend Yield
  • ACOG N/A
  • QNCX N/A
  • EPS Growth
  • ACOG N/A
  • QNCX N/A
  • EPS
  • ACOG N/A
  • QNCX N/A
  • Revenue
  • ACOG $2,928,654.00
  • QNCX N/A
  • Revenue This Year
  • ACOG N/A
  • QNCX N/A
  • Revenue Next Year
  • ACOG N/A
  • QNCX N/A
  • P/E Ratio
  • ACOG N/A
  • QNCX N/A
  • Revenue Growth
  • ACOG N/A
  • QNCX N/A
  • 52 Week Low
  • ACOG $3.75
  • QNCX $0.51
  • 52 Week High
  • ACOG $11.40
  • QNCX $2.45
  • Technical
  • Relative Strength Index (RSI)
  • ACOG N/A
  • QNCX 64.95
  • Support Level
  • ACOG N/A
  • QNCX $1.48
  • Resistance Level
  • ACOG N/A
  • QNCX $1.68
  • Average True Range (ATR)
  • ACOG 0.00
  • QNCX 0.14
  • MACD
  • ACOG 0.00
  • QNCX 0.02
  • Stochastic Oscillator
  • ACOG 0.00
  • QNCX 85.71

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Share on Social Networks: